The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2). Overall, these studies demonstrated ZOLOFT to be superior to placebo on the Hamilton Rating Scale for Depression (HAMD-17) and the Clinical Global Impression Severity (CGI-S) of Illness and Global Improvement (CGI-I) scores. Study MDD-2 was not readily interpretable regarding a dose response relationship for effectiveness. A third study (Study MDD-3) involved adult outpatients meeting the DSM-III criteria for MDD who had responded by the end of an initial 8-week open treatment phase on ZOLOFT 50–200 mg/day. These patients (n=295) were randomized to continuation on double-blind ZOLOFT 50–200 mg/day or placebo for 44 weeks. A statistically significantly lower relapse rate was observed for patients taking ZOLOFT compared to those on placebo: ZOLOFT [n=11 (8%)] and placebo [n=31 (39%)]. Analyses for gender effects on outcome did not suggest any differential responsiveness on the basis of sex. The effectiveness of ZOLOFT in the treatment of OCD was demonstrated in three multicenter placebo-controlled studies of adult (age 18–65) non-depressed outpatients (Studies OCD-1, OCD-2, and OCD-3). All antidepressant drugs are not created equal, according to the authors of one of the few studies that have ever systematically analyzed and compared "new generation" medicines for treating depression. In the analysis of 12 drugs, two came out on top as the most effective and best tolerated as first-line treatments: sertraline (Zoloft) and escitalopram (Lexapro). Venlafaxine (Effexor) and mirtazapine (Remeron) rounded out the top four for effectiveness, but venlafaxine was also among the four drugs patients were most likely to quit taking because of side effects. H., who coauthored a review of the benefits and risks of the same 12 drugs published last November in the Annals of Internal Medicine. Reboxetine (Edronax) was less effective than the rest. Parikh, who wrote a comment accompanying the study that is published in the current issue of The Lancet, says the findings have "enormous implications" because, for the first time, they offer doctors an evidence-based, unbiased way to recommend treatment. He and his colleagues concluded, based on their review done while Gartlehner was at the RTI-UNC Evidence-Based Practice Center in Chapel Hill, North Carolina., that there was no clinically meaningful evidence that any one of the drugs was better than the rest. While psychiatrists treating depressed patients every day have had a sense of which medications are best, the current study "nails it," says Sagar V. And, he adds, they give patients a "gold standard of reliable information," especially since the study's authors plan to make their findings available free on the Web. Instead, they argued, decisions on which drug to use should be based on factors such as cost and side effects. D., of the University of Verona in Italy, and colleagues used a new technique called multiple-treatments meta-analysis to make head-to-head comparisons among the 12 drugs, incorporating 117 randomized controlled trials including 25,928 patients in all. There has been little scientific evidence of the relative effectiveness of these drugs, because most studies compare one against a handful of others or a placebo, and are often funded by the maker of a particular drug, which can bias the findings in its favor, the researchers note. Health.com: How to brighten your winter mood They used two measurements to gauge a drug's effectiveness and tolerability: the percentage of patients who showed at least a 50 percent improvement in their symptoms as measured by one of two scales, or who scored "much improved or very much improved" after eight weeks of treatment (or from six to twelve weeks if eight-week data weren't available) and the percentage of patients who dropped out of the study before eight weeks for any reason.
Objective Sertraline's efficacy and toler- ability in treating generalized anxiety dis- order were evaluated. Method Adult outpatients with DSM-IV generalized. Feb 1, 2013. Most of the Zoloft clinical trials that focused on its efficacy proved to be either negative or neutral. In most of the efficacy studies, Zoloft was not.